{
  "scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "phase III randomized study"
      },
      "Participants": {
        "score": 2,
        "evidence": "high-risk operable patients with non\u2013small cell lung cancer"
      },
      "Intervention": {
        "score": 2,
        "evidence": "comparing stereotactic body radiotherapy and sub-lobar resection (with or without brachytherapy)"
      },
      "Objective": {
        "score": 1,
        "evidence": "to better define the role of these therapies for patients with non\u2013small cell lung cancer"
      },
      "Method_Outcome": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Randomisation_Allocation": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Blinding": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "recently opened for accrual"
      },
      "Number_Analysed": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Result_Outcome": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Harms": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "American College of Surgeons Oncology Group Z4099/Radiation Therapy Oncology Group 1021"
      },
      "Funding": {
        "score": 0,
        "evidence": "Not reported"
      }
    },
    "total_score": 8,
    "max_score": 25
  },
  "model": "gpt-4o"
}